Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Evolve Funds Group Inc. ("Evolve") is pleased to announce the distribution amounts per unit (the "Distributions") for certain funds (the "Evolve Funds"), for the period ending March 31, 2022, as indicated in the table below.